Extension Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Extension Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Extension Study of Two Dosing Schedules of Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis

Inclusion Criteria:

• Subject participated and relapsed in prior PS study

Exclusion Criteria:

• Subject has other active skin diseases
• Multiple concomitant therapy restrictions and/or washouts (topicals, UV, other systemic PS therapies)
• Poorly controlled medical conditions
• History of neurologic symptoms suggestive of central nervous system (CNS) demyelinating disease.
• History of cancer or lymphoproliferative disease
• History of active TB or listeriosis, or persistent chronic or active infections
• Known to have immune deficiency or is immunocompromised
• Clinically significant abnormal laboratory test results
• Erythrodermic psoriasis or generalized pustular psoriasis